alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 177.28 Issuance of advisory rulings and final determinations. ( a ) Pursuant to a request for an advisory ruling which meets the requirements of this subpart, Customs will promptly issue an advisory ruling.
( b ) Pursuant to a request for a final determination which meets the requirements of this subpart, Customs will promptly issue a final determination. If the request does not meet the requirements of this subpart Customs may decline to issue a final determination or may issue instead an advisory ruling.
( c ) Requests for final determinations which include the information set forth in § 177.25(b)(5) (relating to a specific procurement) will be considered by Customs before all other requests (advisory rulings and final determinations).
HomeNRC LibraryDocument CollectionsNUREG-Series PublicationsPublications Prepared by NRC Contractors

# Summary and Categorization of Public Comments on Controlling the Disposition of Solid Materials (NUREG/CR-6682)

Page Last Reviewed/Updated Wednesday, March 24, 2021
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED BALANCE SHEETS AND CONSOLIDATED INCOME STATEMENTS FOR
DELCO REMY INTERNATIONAL, INC. AND SUBSIDIARIES, AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUL-31-1998
<PERIOD-START>                             AUG-01-1997
<PERIOD-END>                               JUL-31-1998
<CASH>                                           8,113
<SECURITIES>                                         0
<RECEIVABLES>                                  128,979
<ALLOWANCES>                                     2,083
<INVENTORY>                                    198,437
<CURRENT-ASSETS>                               369,630
<PP&E>                                         208,537
<DEPRECIATION>                                  50,568
<TOTAL-ASSETS>                                 684,997
<CURRENT-LIABILITIES>                          170,170
<BONDS>                                        393,806
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           245
<OTHER-SE>                                      83,995
<TOTAL-LIABILITY-AND-EQUITY>                   684,997
<SALES>                                        815,313
<TOTAL-REVENUES>                               815,313
<CGS>                                          657,862
<TOTAL-COSTS>                                  657,862
<OTHER-EXPENSES>                               116,866
<LOSS-PROVISION>                                 1,037
<INTEREST-EXPENSE>                              40,291
<INCOME-PRETAX>                                  (134)
<INCOME-TAX>                                      (52)
<INCOME-CONTINUING>                            (2,187)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  1,833
<CHANGES>                                            0
<NET-INCOME>                                   (4,020)
<EPS-PRIMARY>                                    (.20)
<EPS-DILUTED>                                    (.20)
        

</TABLE>
§ 1320.16 Delegation of approval authority. ( a ) OMB may, after complying with the notice and comment procedures of the Administrative Procedure Act, delegate OMB review of some or all of an agency's collections of information to the Senior Official, or to the agency head with respect to those components of the agency for which he or she has not delegated authority.
( b ) No delegation of review authority shall be made unless the agency demonstrates to OMB that the Senior Official or agency head to whom the authority would be delegate: ( 1 ) Is sufficiently independent of program responsibility to evaluate fairly whether proposed collections of information should be approved;
( 2 ) Has sufficient resources to carry out this responsibility effectively; and
( 3 ) Has established an agency review process that demonstrates the prompt, efficient, and effective performance of collection of information review responsibilities.
( c ) OMB may limit, condition, or rescind, in whole or in part, at any time, such delegations of authority, and reserves the right to review any individual collection of information, or part thereof, conducted or sponsored by an agency, at any time.
( d ) Subject to the provisions of this part, and in accordance with the terms and conditions of each delegation as specified in appendix A to this part, OMB delegates review and approval authority to the following agencies: ( 1 ) Board of Governors of the Federal Reserve System; and
( 2 ) Managing Director of the Federal Communications Commission.
§ 10400.22 How will IPEC respond to my Privacy Act request? ( a ) *When will we respond to your request?* We will search to determine if the requested records exist in a system of records IPEC owns or controls. The FOIA Officer will respond to you in writing within 20 days after we receive your request and/or within 10 working days after we receive your request for an amendment, if it meets the requirements of this subpart. We may extend the response time in unusual circumstances, such as the need to consult with another agency about a record or to retrieve a record that is in storage.
( b ) *What will our response include?* ( 1 ) Our written response will include our determination whether to grant or deny your request in whole or in part, a brief explanation of the reasons for the determination, and the amount of the fee charged, if any, under § 10400.24. If you requested access to records, we will make the records, if any, available to you. If you requested amendment of a record, the response will describe any amendments made and advise you of your right to obtain a copy of the amended record.
( 2 ) We will also notify the individual who is subject to the record in writing, if, based on your request, any system of records contains a record pertaining to him or her.
( 3 ) If IPEC makes an adverse determination with respect to your request, our written response will identify the name and address of the person responsible for the adverse determination, that the adverse determination is not a final agency action, and describe the procedures by which you may appeal the adverse determination under § 10400.23.
( 4 ) An adverse determination is a response to a Privacy Act request that: ( i ) Withholds any requested record in whole or in part;
( ii ) Denies a request to amend a record in whole or in part;
( iii ) Declines to provide an accounting of disclosures;
( iv ) Advises that a requested record does not exist or cannot be located;
( v ) Finds that what you requested is not a record subject to the Privacy Act; or
( vi ) Advises on any disputed fee matter.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Antitrust Division

                    Notice is hereby given that, on September 17, 2004, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301*et seq.*                     (“the Act”), the American Society of Civil Engineers (“ASCE”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the name and principal place of business of the standards development organization and (2) the nature and scope of its standards development activities. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.                

                    Pursuant to section 6(b) of the Act, the name and principal place of business of the standards development organization is: American Society of Civil Engineers, Reston, VA. The nature and scope of ASCE's standards development activities are: to develop and publish standards covering a wide range of civil engineering areas, such as structural, geotechnical, transportation, construction, environmental, water and wastewater, coastal and waterway, fire                           ( print page 61865)                        protection, utilities and architectural engineering.                

Dorothy B. Fountain,

Deputy Director of Operations, Antitrust Division.

[FR Doc. 04-23534 Filed 10-20-04; 8:45 am]

BILLING CODE 4410-11-M
NRC NEWS

U.S. NUCLEAR REGULATORY COMMISSION

OFFICE OF PUBLIC AFFAIRS, REGION I

475 Allendale Road

King of Prussia, PA 19406

No. I-00-48 July 5, 2000

CONTACT: Diane Screnci (610)337-5330/ e-mail: dps@nrc.gov

Neil A. Sheehan (610)337-5331/e-mail: nas@nrc.gov

NRC TO HOLD PUBLIC MEETING NEAR CALVERT CLIFFS NUCLEAR PLANT

ON CHANGES IN REACTOR OVERSIGHT

The Nuclear Regulatory Commission has scheduled a public meeting for Wednesday, July 12,

in Solomons, Md., to discuss the agency’s new reactor oversight process. The process was initiated in

April at the Calvert Cliffs Nuclear Power Plant and other commercial nuclear power plants nationwide.

The meeting will begin at 7 p.m. at the Holiday Inn Select in Solomons, Md. Members of the

public will have the opportunity to ask questions of NRC staff during and after the meeting.

The new oversight process uses more objective, timely and safety-significant criteria in

assessing performance while seeking to more effectively and efficiently regulate the industry. Under

the new process, inspections by NRC resident inspectors and regional office-based personnel are

supplemented by statistical measures of plant activities called performance indicators. These

performance indicators measure important safety aspects of plant operations, including the viability of

redundant safety systems, emergency planning, radiation protection and security measures.

Inspection findings and performance indicators for each nuclear power plant are posted on the

NRC’s web site every three months. The safety significance of each inspection finding or performance

indicator is characterized by a color -- green, white, yellow or red.

The NRC response to the inspection finding and performance indicators will be based on the

significance of the items. A green finding receives normal NRC oversight, while white, yellow or red

assessments receive increasing NRC involvement. Multiple red findings could result in a plant

shutdown.

A plain language summary of the reactor oversight process is available from the NRC Office of

Public Affairs or on the web site at: www.nrc.gov/OPA/primer.htm

Detailed information regarding the reactor oversight process is available on the web site at:

www.nrc.gov/NRR/OVERSIGHT/ASSESS/index.html

#
NRC NEWS

UNITED STATES NUCLEAR REGULATORY COMMISSION

OFFICE OF PUBLIC AFFAIRS, REGION II

61 Forsyth Street SW, Atlanta GA 30303

Web Site: www.nrc.gov

No. II-03-036 July 18, 2003

CONTACT: Ken Clark (404)562-4416 E-mail: OPA2@nrc.gov

Roger Hannah (404)562-4417

MUSSER NAMED NRC SENIOR RESIDENT INSPECTOR

AT HARRIS NUCLEAR PLANT

U. S. Nuclear Regulatory Commission officials in the Region II office in Atlanta have

announced the assignment of Randall A. (Randy) Musser as the new Senior Resident Inspector at the

Shearon Harris Nuclear Plant southwest of Raleigh, North Carolina.

Musser had been the Senior Resident Inspector at the Surry Nuclear Power Station in

southeastern Virginia since August 1996. He is a native of Pittsburgh, Pennsylvania, and in 1982,

received his Bachelor of Science degree in Marine (Mechanical) Engineering from the U.S. Merchant

Marine Academy in Kings Point, New York. He began his career with Charleston Naval Shipyard,

where he was assigned to the Nuclear Engineering Department’s Reactor Engineering Division as a

Shift Refueling Engineer. When Musser joined the NRC in 1987, he became the Resident Inspector at

the Hatch Nuclear Plant near Baxley, Georgia. In 1992, he transferred to the Browns Ferry Nuclear

Plant near Athens. Alabama, where he was the primary Resident Inspector for Browns Ferry Unit 3, a

unit undergoing recovery following a long-term shutdown.

Each U.S. commercial nuclear power plant has assigned NRC resident inspectors who serve as

the agency’s eyes and ears at the facility, conducting regular inspections, monitoring significant work

projects and interfacing with plant workers and the public. 

Musser joins NRC Resident Inspector Bob Hagar and Site Secretary Ann Kroeger at the Harris

plant. The NRC inspectors at Harris can be reached at 919-362-0601.

###
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

      ( print page 64851)    
Pursuant to section 10(d) of the Federal Advisory Committee Act, notice is hereby given of the following meeting. 

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Aging Special Emphasis Panel; Inflammation and Independence in Seniors.                    

*Date:*                         January 8, 2019.                    

*Time:*                         12:00 p.m. to 2:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20814.                    

*Contact Person:*                         Anita H. Undale, Ph.D., Scientific Review Branch, National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, 240-747-7825,                         *anita.undale@nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: December 11, 2018.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018-27182 Filed 12-17-18; 8:45 am]

 BILLING CODE 4140-01-P
Exhibit 31.2
 
 Certification of the Principal Financial Officer
 (Section 302 of the Sarbanes-Oxley Act of 2002)
 
 I, Bruce Winston, certify that:
 
 1.  I have reviewed this annual report on Form 10-K of Guaranty Federal Bancshares, Inc.;
 
 2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
 3.  Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this   report;
 
 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:
 
 a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 b) [Reserved  not effective]
 
 c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 d) Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants  most recent  fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and
 
 5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal controls over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
 
 a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
 b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
 Date:   March 30, 2004      /s/ Bruce Winston
 Bruce Winston
  Chief Financial Officer
 (Principal Financial Officer)
#### The People of the State of New York, Respondent, v. William Wilkinson, Appellant.

Appeal dismissed upon stipulation filed.
[Federal Register Volume 69, Number 24 (Thursday, February 5, 2004)]
[Notices]
[Page 5548]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-2396]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Diagnostics of Fungal 
Infections

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide, limited 
field of use, exclusive license to practice the inventions embodied in 
the patent application referred to below to TNB Laboratories, Inc. 
(TNB) having a place of business in St. Johns, Newfoundland. The patent 
rights in these inventions have been assigned to the government of the 
United States of America. The patent application to be licensed is:
    Title: ``Latent Human Tuberculosis Model, Diagnostic Antigens, and 
Methods of Use,'' U.S. Patent Application Serial No.: 10/250,930 (TBC).
    Status: Pending.
    Issue Date: N/A.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Technology

    This technology adds a new level of specificity in the 
identification of Tuberculosis. It can be incorporated into a device to 
diagnose Latent Human Tuberculosis.

ADDRESSES: Requests for a copy of this patent application, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Andrew Watkins, Director, Technology Transfer 
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford 
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; 
facsimile: (770) 488-8615. Applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by CDC within sixty days of this notice will 
be considered. Comments and objections submitted in response to this 
notice will not be made available for public inspection, and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552. A signed Confidential Disclosure 
Agreement (available under Forms @ http://www.cdc.gov/tto) will be 
required to receive a copy of any pending patent application.

    Dated: January 29, 2004.
Joseph R. Carter,
Deputy Chief Operating Officer, Centers for Disease Control and 
Prevention.
[FR Doc. 04-2396 Filed 2-4-04; 8:45 am]
BILLING CODE 4163-18-P